Marvel Biosciences
C$0.09
0
-C$0.01-10.53% Friday 20:52
Statistics
Day High
0.1
Day Low
0.09
52W High
0.15
52W Low
0.01
Volume
30,000
Avg. Volume
34,745
Mkt Cap
4.97M
P/E Ratio
-
Dividend Yield
-
Dividend
-
Upcoming
Earnings
15FebExpected
Q3 2023
Next
999
333
-333
-999
Expected EPS
N/A
Actual EPS
N/A
People Also Follow
This list is based on the watchlists of people on Stock Events who follow MRVL.V. It's not an investment recommendation.
About
Marvel Biosciences Corp. operates as a pre-clinical stage pharmaceutical development biotechnology company. It engages in the discovery and development of synthetic derivative compounds of known drugs that inhibit the A2a adenosine receptor. The company offers Nourianz (Istradefylline, KW-6002), an adenosine A2A receptor antagonist. It targets neurological diseases, such as Alzheimer's disease, depression and anxiety, and addictions; non-neurological conditions of cancer; and non-alcoholic steatohepatitis. Marvel Biosciences Corp. is headquartered in Calgary, Canada.
Show more...
CEO
Mr. J. Roderick Matheson
Country
CA
ISIN
CA57384M1077